Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose To evaluate the frequency and outcome of haemorrhagic transformation (HT) after ischaemic stroke in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Methods Patients with stroke on treatment with a NOAC were prospectively enrolled in this multicentre observational study between February 2012 and 2015. Brain imaging at admission and follow-up imaging until day 7 were reviewed for HT. Functional outcome was assessed by the modified Rankin scale (mRS) before the index event, at discharge, and at 3-months. Results 231 patients without recanalisation therapy (no-RT), and 32 patients with RT were eligible for analysis. Any HT was present at admission in 9/231 no-RT patients (3.9%, 95% CI 2.0 to 7.3) and in none of the patients with RT. In patients with follow-up imaging (no-RT, n=129, and RT, n=32), HT was present in 14.0% (no-RT; 95% CI, 8.9 to 21.1), and 40.6% (RT, 95% CI, 25.5 to 57.8), respectively. After adjustment for stroke severity, this difference between the no-RT and RT groups became non-significant. Symptomatic ICH was observed in 1 patient per group. HT was not associated with unfavourable outcome (mRS 3-6) at 3-months in multivariable analysis. Resumption of OAC after stroke was delayed in patients with HT compared to those without (15 d [IQR, 5–26] vs. 1 d [0–4], P<0.001). Conclusions The frequency and severity of HT after stroke on NOAC appears similar to previous reports for vitamin K antagonists and no anticoagulation. Whether asymptomatic HT should delay resumption of preventive anticoagulation requires further investigation.
Abstract
Background and Purpose To evaluate the frequency and outcome of haemorrhagic transformation (HT) after ischaemic stroke in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Methods Patients with stroke on treatment with a NOAC were prospectively enrolled in this multicentre observational study between February 2012 and 2015. Brain imaging at admission and follow-up imaging until day 7 were reviewed for HT. Functional outcome was assessed by the modified Rankin scale (mRS) before the index event, at discharge, and at 3-months. Results 231 patients without recanalisation therapy (no-RT), and 32 patients with RT were eligible for analysis. Any HT was present at admission in 9/231 no-RT patients (3.9%, 95% CI 2.0 to 7.3) and in none of the patients with RT. In patients with follow-up imaging (no-RT, n=129, and RT, n=32), HT was present in 14.0% (no-RT; 95% CI, 8.9 to 21.1), and 40.6% (RT, 95% CI, 25.5 to 57.8), respectively. After adjustment for stroke severity, this difference between the no-RT and RT groups became non-significant. Symptomatic ICH was observed in 1 patient per group. HT was not associated with unfavourable outcome (mRS 3-6) at 3-months in multivariable analysis. Resumption of OAC after stroke was delayed in patients with HT compared to those without (15 d [IQR, 5–26] vs. 1 d [0–4], P<0.001). Conclusions The frequency and severity of HT after stroke on NOAC appears similar to previous reports for vitamin K antagonists and no anticoagulation. Whether asymptomatic HT should delay resumption of preventive anticoagulation requires further investigation.
참고문헌 (39)
- Lindley RI, "Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction", J Stroke Cerebrovasc Dis, 13, pp.235~246 (2004)
- Paciaroni M, "Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study", Stroke, 39, pp.2249~2256 (2008)
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Alvarez-Sabin J, "Factors influencing haemorrhagic transformation in ischaemic stroke", Lancet Neurol, 12, pp.689~705 (2013)
- O’Donnell M, "Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study", Lancet Neurol, 5, pp.749~754 (2006)
- Easton JD, "Definition and evaluation of transient ischemic attack", Stroke, 40, pp.2276~2293 (2009)
- Lip GY, "Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study", Chest, 144, pp.1839~1847 (2013)
- Lip GY, "Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal", Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs, J Am Coll Cardiol, pp.2011, 57[DOI]
- Purrucker JC, "Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants", Stroke, 47, pp.1127~1130 (2016)
- Haacke EM, "Susceptibility-weighted imaging: technical aspects and clinical applications, part 1", Am J Neuroradiol, 30, pp.19~30 (2009)
- Hacke W, "Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)", JAMA, 274, pp.1017~1025 (1995)
- Hacke W, "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators", Lancet, 352, pp.1245~1251 (1998)
- Barber PA, "Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score", Lancet, 355, pp.1670~1674 (2000)
- Puetz V, "Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion", Stroke, 39, pp.2485~2490 (2008)
- Agresti A, "Approximate is better than “exact” for interval estimation of binomial proportions", The American Statistician, 52, pp.119~126 (1998)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Kirchhof P, "A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network", European Heart Rhythm Association consensus conference, 2016, pp.18, 37~50
- Huisman MV, "Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II", Am J Med, 128, pp.1306~1313 (2015)
- Hart RG, "Embolic strokes of undetermined source: the case for a new clinical construct", Lancet Neurol, 13, pp.429~438 (2014)
- Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Purrucker JC, "Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants", JAMA Neurol, 73, pp.169~177 (2016)
- Pfeilschifter W, "Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice", Stroke, 42, pp.1116~1121 (2011)
- Bohmann F, "No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke", PLoS ONE, 7, pp.e40804~ (2012)
- Gliem M, "Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice", Stroke, 43, pp.3352~3357 (2012)
- Heidbuchel H, "European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation", Europace, 15, pp.625~651 (2013)
- Lees KR, "Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials", Lancet, 375, pp.1695~1703 (2010)
- Park JH, "Is asymptomatic hemorrhagic transformation really innocuous?", Neurology, 78, pp.421~426 (2012)
- Lei C, "Asymptomatic hemorrhagic transformation after acute ischemic stroke: is it clinically innocuous?", J Stroke Cerebrovasc Dis, 23, pp.2767~2772 (2014)
- Dzialowski I, "Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry", Stroke, 38, pp.75~79 (2007)
- Jickling GC, "Hemorrhagic transformation after ischemic stroke in animals and humans", J Cereb Blood Flow Metab, 34, pp.185~199 (2014)
- Kimura K, "Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke", J Neurol Neurosurg Psychiatry, 76, pp.679~683 (2005)
- Hylek EM, "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation", N Engl J Med, 349, pp.1019~1026 (2003)
- Audebert HJ, "Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation", Cerebrovasc Dis, 29, pp.476~483 (2010)
- Kate M, "Dabigatran Therapy in Acute Ischemic Stroke Patients Without Atrial Fibrillation", Stroke, 46, pp.2685~2687 (2015)
- Gioia LC, "Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation: A Prospective Magnetic Resonance Imaging Study", Stroke, 47, pp.1917~1919 (2016)
- Baird AE, "A three-item scale for the early prediction of stroke recovery", Lancet, 357, pp.2095~2099 (2001)